Health News

The latest information for the health professional

08 October, 2020 Health News

Efficacy and Safety of New Oral Immunotherapy Drug on Peanut Allergies

Efficacy and Safety of New Oral Immunotherapy Drug on Peanut Allergies


Researchers have published a study in the journal The Lancet Child & Adolescent Health that examined the efficacy and safety of a new oral biologic drug called AR101 against peanut allergies.


The trial was conducted in several countries across Europe with a focus on children with peanut allergies aged 4 to 17 years.
 
For the trial, 227 children were randomly split into a daily dose of AR101 or a placebo group, and the dose was increased every two weeks over a six-month period. At the end of the six months, participants were receiving a dose of 300 mg peanut protein.
 
At the end of the trial, the researchers found that 58% of the individuals in the control group tolerated 1000mg of peanut protein versus 2% of the individuals in the placebo group. Although adverse events were reported by almost all of the individuals, the severity level for most participants in both groups was mild or moderate. In conclusion, AR101 oral immunotherapy treatment led to a desensitization to peanut protein and provided a predictable safety profile.
 
Hourihane, J. O. B., Beyer, K., Abbas, A., Fernández-Rivas, M., Turner, P. J., Blumchen, K., ... & Sharma, V. (2020). Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. The Lancet Child & Adolescent Health.
Cookies Policy

This site may use some cookies to enhance user experience. Please, accept it before navigate in our website. We recommend you to read the cookies policy .